DK3706739T3 - Anvendelse af riluzolprodrugs til behandling af ataksier - Google Patents

Anvendelse af riluzolprodrugs til behandling af ataksier Download PDF

Info

Publication number
DK3706739T3
DK3706739T3 DK18876779.2T DK18876779T DK3706739T3 DK 3706739 T3 DK3706739 T3 DK 3706739T3 DK 18876779 T DK18876779 T DK 18876779T DK 3706739 T3 DK3706739 T3 DK 3706739T3
Authority
DK
Denmark
Prior art keywords
rilusol
ataxias
products
treatment
rilusol products
Prior art date
Application number
DK18876779.2T
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Melissa Beiner
Gilbert L'italien
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3706739(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Application granted granted Critical
Publication of DK3706739T3 publication Critical patent/DK3706739T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18876779.2T 2017-11-12 2018-11-11 Anvendelse af riluzolprodrugs til behandling af ataksier DK3706739T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US201862717948P 2018-08-13 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
DK3706739T3 true DK3706739T3 (da) 2024-12-02

Family

ID=66438598

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18876779.2T DK3706739T3 (da) 2017-11-12 2018-11-11 Anvendelse af riluzolprodrugs til behandling af ataksier
DK24199849.1T DK4483956T3 (da) 2017-11-12 2018-11-11 Troriluzol til anvendelse i behandlingen af spinocerebellar ataksi 3 (sca3)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK24199849.1T DK4483956T3 (da) 2017-11-12 2018-11-11 Troriluzol til anvendelse i behandlingen af spinocerebellar ataksi 3 (sca3)

Country Status (26)

Country Link
US (3) US20210023061A1 (da)
EP (4) EP4483956B1 (da)
JP (2) JP7352542B2 (da)
KR (2) KR20200103658A (da)
CN (1) CN112292127A (da)
AU (1) AU2018364749C1 (da)
BR (1) BR112020009173A2 (da)
CA (1) CA3082096A1 (da)
DK (2) DK3706739T3 (da)
ES (1) ES2996892T3 (da)
FI (2) FI4483956T3 (da)
HR (1) HRP20241675T1 (da)
HU (1) HUE070302T2 (da)
IL (1) IL274532B2 (da)
LT (2) LT4483956T (da)
MD (1) MD3706739T2 (da)
MX (2) MX2020004678A (da)
PH (1) PH12020550583A1 (da)
PL (1) PL3706739T3 (da)
PT (2) PT3706739T (da)
RS (2) RS66277B1 (da)
SG (1) SG11202004332XA (da)
SI (1) SI3706739T1 (da)
SM (2) SMT202500022T1 (da)
WO (1) WO2019094851A1 (da)
ZA (1) ZA202002626B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639298B2 (en) 2015-03-03 2020-05-05 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2023081860A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
JP2025517509A (ja) * 2022-05-23 2025-06-05 バイオヘイブン・セラピューティクス・リミテッド 脊髄小脳失調症を治療する方法
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
ATE323467T1 (de) 1997-07-25 2006-05-15 Alpex Pharma Sa Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
DE60222160T2 (de) 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
DK1477166T3 (da) * 2003-04-28 2006-12-11 Biofrontera Bioscience Gmbh Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1978939A2 (en) 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
EP2271344A4 (en) * 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US10639298B2 (en) * 2015-03-03 2020-05-05 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use

Also Published As

Publication number Publication date
AU2018364749A1 (en) 2020-07-02
US12102618B2 (en) 2024-10-01
LT4483956T (lt) 2026-04-27
AU2018364749B2 (en) 2023-11-09
ZA202002626B (en) 2025-02-26
EP4483956A2 (en) 2025-01-01
BR112020009173A2 (pt) 2020-11-03
AU2018364749C1 (en) 2024-02-15
US20230355592A1 (en) 2023-11-09
IL274532B2 (en) 2024-05-01
HRP20241675T1 (hr) 2025-02-14
EP3706739A1 (en) 2020-09-16
PT4483956T (pt) 2026-03-16
CN112292127A (zh) 2021-01-29
SG11202004332XA (en) 2020-06-29
RS67956B1 (sr) 2026-04-30
EP4483956A3 (en) 2025-03-19
CA3082096A1 (en) 2019-05-16
MX2023012640A (es) 2023-11-08
RS66277B1 (sr) 2025-01-31
US20210023061A1 (en) 2021-01-28
JP2023175823A (ja) 2023-12-12
EP4696324A2 (en) 2026-02-18
KR20250034521A (ko) 2025-03-11
KR20200103658A (ko) 2020-09-02
EP4699619A3 (en) 2026-05-06
ES2996892T3 (en) 2025-02-13
JP7352542B2 (ja) 2023-09-28
US20230390252A1 (en) 2023-12-07
PH12020550583A1 (en) 2021-05-31
IL274532B1 (en) 2024-01-01
FI3706739T3 (fi) 2024-12-27
EP3706739B1 (en) 2024-10-16
WO2019094851A1 (en) 2019-05-16
SMT202500022T1 (it) 2025-03-12
EP3706739A4 (en) 2021-08-04
HUE070302T2 (hu) 2025-05-28
SMT202600156T1 (it) 2026-05-12
IL274532A (en) 2020-06-30
EP4699619A2 (en) 2026-02-25
DK4483956T3 (da) 2026-03-23
FI4483956T3 (fi) 2026-03-16
SI3706739T1 (sl) 2025-03-31
LT3706739T (lt) 2024-12-27
NZ765220A (en) 2023-11-24
PT3706739T (pt) 2024-12-04
MX2020004678A (es) 2020-08-13
EP4696324A3 (en) 2026-05-06
PL3706739T3 (pl) 2025-03-10
MD3706739T2 (ro) 2025-02-28
EP4483956B1 (en) 2025-12-31
JP2021502392A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
DK3562486T3 (da) Anvendelse af sublingual dexmedetomidin til behandling af agitation
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
EP3564335A4 (en) SURFACE TREATMENT AGENT
DK3160234T3 (da) Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
PL3672948T3 (pl) Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
IL251904A0 (en) Apilimod for use in the treatment of melanoma
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf